Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nature Clinical Practice Oncology

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ncponc0558PMID 16894390
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Targeted agents for the treatment of advanced renal cell carcinoma.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• The transcriptional repressor Snail promotes mammary tumor recurrence.

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005influential reference
• Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

  2005cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo

  2005cited by this paper
• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

  2005cited by this paper
• Cancer Invasion and Metastasis

  2005cited by this paper
• Drug discovery: Playing dirty

  2005cited by this paper
• Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

  2005cited by this paper
• Self-Renewal and Cancer of the Gut: Two Sides of a Coin

  2005cited by this paper
• Genomics and proteomics--the way forward.

  2005cited by this paper
• Brief communication: a new combination in the treatment of advanced pancreatic cancer.

  2005cited by this paper
• The disparate role of BMP in stem cell biology

  2005cited by this paper
• Targeted agents for the treatment of advanced renal cell carcinoma

  2005cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• The Akt/PKB pathway: molecular target for cancer drug discovery

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer

  2005cited by this paper
• Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma.

  2005cited by this paper
• Epigenetics in human disease and prospects for epigenetic therapy

  2004cited by this paper
• A resource for large-scale RNA-interference-based screens in mammals

  2004cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Oncogene addiction: sometimes a temporary slavery.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• The development of proteasome inhibitors as anticancer drugs.

  2004cited by this paper
• Targeted cancer therapy

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Engineering complex systems

  2004cited by this paper
• The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma

  2004influential reference
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Molecular Networks: The Top-Down View

  2003cited by this paper
• Biological Networks: The Tinkerer as an Engineer

  2003cited by this paper
• Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.

  2003cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma.

  2003cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.

  2003cited by this paper
• Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

  2003cited by this paper
• Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.

  2002cited by this paper
• Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC

  2002cited by this paper
• Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

  2002cited by this paper
• Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

  2002cited by this paper
• Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression

  2002cited by this paper
• Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade

  2002cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• Stable suppression of tumorigenicity by virus-mediated RNA interference.

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Cancer gene therapy: fringe or cutting edge?

  2001cited by this paper
• Mechanism of action of anti-HER2 monoclonal antibodies.

  2001cited by this paper
• Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

  2001cited by this paper
• Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

  2001cited by this paper
• Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis.

  2000cited by this paper
• Reversibility of acute B-cell leukaemia induced by BCR–ABL1

  2000cited by this paper
• Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.

  1999cited by this paper
• Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.

  1999cited by this paper
• Reversible tumorigenesis by MYC in hematopoietic lineages.

  1999cited by this paper
• Essential role for oncogenic Ras in tumour maintenance

  1999cited by this paper
• Gene expression profiling, genetic networks, and cellular states: an integrating concept for tumorigenesis and drug discovery

  1999cited by this paper
• Suppression of Ki‐ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki‐ras mutation but not those without Ki‐ras mutation

  1997cited by this paper
• Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.

  1997cited by this paper
• Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

  1997cited by this paper
• Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells.

  1995influential reference
• erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.

  1994cited by this paper
• Apoptosis. Its significance in cancer and cancer Therapy

  1994cited by this paper
• Cancer invasion and metastasis.

  1993cited by this paper

• Ulcerative Colitis after Administration of Dupilumab, an Anti-interleukin-4 Receptor Subunit α Monoclonal Antibody: A Case Report.

  2025cites this paper
• Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib

  2025cites this paper
• Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML

  2025cites this paper
• Breaking the script: transcriptional addiction as a driver of genome instability in cancer.

  2025cites this paper
• WITHDRAWN: OncoStratifier: Stratifying Oncogene-addicted Cohorts By Drug Response

  2025cites this paper
• Targeting PI4KB and Src/Abl host kinases as broad-spectrum antiviral strategy: myth or real opportunity?

  2025cites this paper
• Casual association between immune cells and colorectal cancer: A Mendelian Randomization Study

  2025cites this paper
• Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression

  2025cites this paper
• Oncogene Mutations: The Shared Antigen Vaccines That Work?

  2025cites this paper
• Mediator kinase inhibition drives myometrial stem cell differentiation and the uterine fibroid phenotype through super-enhancer reprogramming

  2025cites this paper
• The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies

  2025cites this paper
• The Profile of Gut Microbiota in Carcinogenesis Driven by Mutant EGFR in Non–Small Cell Lung Cancer

  2025cites this paper
• Molecular docking and pharmacophore analysis of trisindoline 1 against human topoisomerase II and human derived growth factor

  2024cites this paper
• Methodical selected coptisine attenuates the malignancy of cholangiocarcinoma through the blockade of EGFR signalling

  2024cites this paper
• Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer

  2024cites this paper
• DNA G-Quadruplexes as Targets for Natural Product Drug Discovery

  2024cites this paper
• High expression of YEATS2 as a predictive factor of poor prognosis in patients with hepatocellular carcinoma

  2024cites this paper
• EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis

  2024cites this paper
• Theoretical guiding with molecular docking for the screening of high-sensitive AIE probes for specific protein detection.

  2024cites this paper
• Effects of post-fermentation addition of green tea extract for sulfur dioxide replacement on Sauvignon Blanc wine phenolic composition, antioxidant capacity, colour, and mouthfeel attributes.

  2024cites this paper
• Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

  2024cites this paper
• Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

  2024cites this paper
• Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction.

  2024cites this paper
• Lineage-Selective Dependencies in Pediatric Cancers.

  2024cites this paper
• Ecological and evolutionary dynamics to design and improve ovarian cancer treatment

  2024cites this paper
• PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors

  2024cites this paper
• Canonical and Noncanonical Functions of the BH3 Domain Protein Bid in Apoptosis, Oncogenesis, Cancer Therapeutics, and Aging

  2024cites this paper
• ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

  2024cites this paper
• Non-oncogene dependencies: Novel opportunities for cancer therapy.

  2024cites this paper
• Mediator kinase inhibition drives myometrial stem cell differentiation and the uterine fibroid phenotype through super-enhancer reprogramming

  2024cites this paper
• From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer

  2024cites this paper
• DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF ENTRECTINIB NANOSPONGES LOADED TABLETS FOR ORAL DELIVERY

  2023cites this paper
• New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer

  2023cites this paper
• Transcriptional background effects on a tumor driver gene in different pigment cell types of medaka.

  2023cites this paper
• RNF126, 168 and CUL1: The Potential Utilization of Multi-Functional E3 Ubiquitin Ligases in Genome Maintenance for Cancer Therapy

  2023cites this paper
• A Cell‐Penetrant Peptide Disrupting the Transcription Factor CP2c Complexes Induces Cancer‐Specific Synthetic Lethality

  2023cites this paper
• Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma

  2023cites this paper
• Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators

  2023cites this paper
• Molecular basis of sex differences in cancer: Perspective from Asia

  2023cites this paper
• DEVELOPMENT OF TARGETED DRUG COMBINATIONS BLOCKING MULTI-DRIVER ONCOGENESIS

  2023cites this paper
• Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors

  2023cites this paper
• Formulation Development, Optimization, and Characterization of Entrectinib-Loaded Supersaturable Self-Nanoemulsifying Drug Delivery Systems

  2023cites this paper
• New therapies for clear cell ovarian carcinoma

  2023cites this paper
• Targeted therapy for lung cancer: Beyond EGFR and ALK

  2023cites this paper
• The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells

  2023cites this paper
• Exploring the adsorption performance of doped graphene quantum dots as anticancer drug carriers for cisplatin by DFT, PCM, and COSMO approaches

  2023cites this paper
• Transcriptional background effects on a tumor driver gene in a transgenic medaka melanoma model

  2022cites this paper
• Crescent‐Shaped Carbazole Derivatives as Light‐Up Fluorescence Probes for G‐Quadruplex DNA and Live Cell Imaging

  2022cites this paper
• MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements

  2022cites this paper
• Defektif Homolog Rekombinasyon DNA Tamiri ve PARP İnhibisyonu Arasındaki Sentetik Letal Etkileşim

  2022cites this paper
• White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy

  2022cites this paper
• The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy

  2022cites this paper
• LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer

  2022cites this paper
• Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer.

  2022cites this paper
• Dual therapeutic approach to modulate Glycogen Synthase kinase -3 beta (GSK-3Β) and inhibitor of nuclear factor kappa kinase-beta (IKK-β) receptors by in silico designing of inhibitors.

  2022cites this paper
• The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets.

  2022cites this paper
• ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer.

  2022cites this paper
• Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities

  2022cites this paper
• Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection

  2022cites this paper
• The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells

  2022cites this paper
• Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights

  2022cites this paper
• CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

  2022cites this paper
• LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer

  2022cites this paper
• Kanserde Hedefe Yönelik Tedavi: PI3K/Akt/mTOR İnhibitörleri

  2022cites this paper
• Super-Enhancers Dysregulations in Hematological Malignancies

  2022cites this paper
• Analysis of CCND1 protein and circulatory antioxidant enzyme activity association in oral squamous cell carcinoma

  2021cites this paper
• Drug delivery systems in cancer therapy

  2021cites this paper
• Tilting MYC toward cancer cell death.

  2021cites this paper
• Estrogen Receptor Positive Breast Cancer: 8p11-p12 Amplicon and Therapeutic Response

  2021cites this paper
• Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors

  2021cites this paper
• Multiplexed Protein Biomarker Detection with Microfluidic Electrochemical Immunoarrays.

  2021cites this paper
• Potential Therapies and Diagnosis Based on Golgi-targeted Nano Drug Delivery Systems.

  2021cites this paper
• E1 Enzymes as Therapeutic Targets in Cancer

  2021cites this paper
• Targeting Non-Oncogene Addiction for Cancer Therapy

  2021cites this paper
• Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer

  2021cites this paper
• In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)

  2021cites this paper
• A DNA dendrimer amplified electrochemical immunosensing method for highly sensitive detection of prostate specific antigen.

  2021cites this paper
• Capturing cancer evolution using genetically engineered mouse models (GEMMs).

  2021cites this paper
• Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3–amplified lung adenocarcinoma cells

  2021cites this paper
• D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy

  2021cites this paper
• VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells

  2021cites this paper
• Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors

  2021cites this paper
• WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth

  2021cites this paper
• Our Journey Beyond Sunset Boulevard: Evidence-Based Analysis of Tumor-Targeted Cancer Gene Therapy Shines a Critical Spotlight on Long-Term Cancer-Free Survival

  2021cites this paper
• Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report

  2021cites this paper
• Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system.

  2021cites this paper
• Prognostic and Clinicopathological Significance of CCND1/Cyclin D1 Upregulation in Melanomas: A Systematic Review and Comprehensive Meta-Analysis

  2021cites this paper
• Mechanisms of breast cancer metastasis

  2021cites this paper
• Cancer as a form of life: Musings of the cancer and evolution symposium.

  2021cites this paper
• Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4

  2021cites this paper
• Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy

  2021cites this paper
• Pancreatic cancer.

  2021cites this paper
• Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• Rapamycin Inhibitors for Eye Squamous Cell Carcinoma after Renal Transplantation: A Case Report

  2021cites this paper
• Amivantamab: Treating EGFR Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation.

  2021cites this paper
• Models of Cancer Drug Discovery and Response to Therapy

  2021cites this paper
• Targeting Oncogene Addiction for Cancer Therapy

  2021cites this paper
• Oncogenic Functions and Therapeutic Targeting of EphA2 in Cancer

  2021cites this paper
• The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer

  2021cites this paper
• Liquid biopsy

  2021cites this paper